GSK256471 is a potent selective NK(3) antagonist that shows a high affinity for recombinant human (PK (I) value 8.9) and native guinea pig (PK (I) value 8.4) tachykinin NK(3) receptors. In vitro functional assessment showed that GSK256471 reduced the E(Ma
D-Lysine lactam is a chiral building block.1,2It has been used in the synthesis of a chiral antibiotic synthetic intermediate, as well as in the stereoselective synthesis of neurokinin (NK) receptor antagonists. 1.Kumar, A., Bhashkar, B., Bhavsar, J., et al.Catalytic reduction: Efficient synthesis of chiral key intermediate of besifloxacin hydrochlorideDer Pharma Chemica7(9)297-3000(2015) 2.Gerspacher, M., Lewis, C., Ball, H.A., et al.Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonistJ. Med. Chem.46(16)3508-3513(2003)
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) 是一种 Substance P 类似物,在大鼠大脑中对神经激肽 1 受体 (NK1R) 的作用与 Substance P 大致相等,但作用时间大大延长。[Glp5,(Me)Phe8,Sar9] Substance P (5-11) 能选择性地激活大鼠大脑间脑和中脑皮层的多巴胺代谢。[Glp5,(Me)Phe8,Sar9] Substance P (5-11) 还可增加大鼠运动活性,诱导成瘾剂寻求行为的恢复。